Skip to content
Home/Companies/Pharma/Advencis

Advencis

Pharma·Europe·Exited 2014·Held 2yr
Entry
2012
Hold
2yr
Exit
2014

Who owns Advencis?

Advencis is a Pharma company based in Europe, now owned by bioMerieux, which acquired it in 2014 from Merieux Equity Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Merieux Equity Partners
Investor
Merieux Equity Partners
Mérieux Innovation 1 · 2014 · VC

Key facts

HQEurope
SectorPharma
StatusAcquired
Exit Type
Trade Sale
Buyer
bioMerieux
Exit Year
2014

More from Mérieux Innovation 1

Other portfolio companies in the same fund.

Broken String Biosciences
Broken String Biosciences
Active
BiotechUK· 2023
InnoSyn
InnoSyn
Active
PharmaNetherlands· 2023
LabQuality
LabQuality
Exited 2025
HealthcareFrance· 2023
to Aurevia
Cairdac
Cairdac
Active
MedTechFrance· 2022
Mablink Bioscience
Exited 2023
BiotechFrance· 2022
to Eli Lilly and Company
SeqOne Genomics
SeqOne Genomics
Active
BiotechFrance· 2022

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns Advencis?

Advencis is now owned by bioMerieux, which acquired it in 2014 from Merieux Equity Partners.

When did bioMerieux acquire Advencis?

bioMerieux acquired Advencis in 2014, buying from Merieux Equity Partners.

Who did Advencis sell to?

Merieux Equity Partners sold Advencis to bioMerieux in 2014 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue